<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966315</url>
  </required_header>
  <id_info>
    <org_study_id>B-1307/212-010</org_study_id>
    <nct_id>NCT01966315</nct_id>
  </id_info>
  <brief_title>The Comparison of Dexmedetomidine and Midazolam for the Sleep in Intensive Care Unit</brief_title>
  <official_title>The Comparison of Dexmedetomidine and Midazolam for the Sleep of Mechanical Ventilated Intensive Care Unit Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are going to compare the sleep quality and quantity between dexmedetomidine
      group and midazolam group using 24 hour polysomnography in critically ill patients. And the
      investigators also compare the incidence of delirium between the two groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep is very important for cognitive and immune function. However, patients in intensive
      care unit (ICU) have a very poor sleep.

      Almost all ventilated patients in intensive care unit (ICU) take a sedative drug. In Korea,
      most commonly used sedative drugs are dexmedetomidine and midazolam.

      The investigators are going to compare the sleep quality and quantity between dexmedetomidine
      group and midazolam group using 24 hour polysomnography. And the investigators also compare
      the incidence of delirium between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The differences of sleep stage, sleep efficiency, arousal index and delirium between dexmedetomidine group and midazolam group</measure>
    <time_frame>during ICU stay</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Poor Quality Sleep</condition>
  <condition>Sleep Deprivation</condition>
  <condition>Sleep Arousal Disorders</condition>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <description>Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.
They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam group</arm_group_label>
    <description>Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.
They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Critical patients who take a sedative drugs (dexmedetomidine or midazolam).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sedation patients with dexmedetomidine or midazolam

          -  over 18 years old

        Exclusion Criteria:

          -  Neurologic disease (stroke, seizure, dementia, hypoxic brain damage)

          -  Brain infection

          -  Alcoholics

          -  Major Depression Disorder, Schizophrenia, Anxiety disorder

          -  Hearing loss
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Jae Cho, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi, Republic of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Jae Cho, MPH</last_name>
    <phone>+82-10-9928-1081</phone>
    <email>lungdrcho@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Se Joong Kim, PhD</last_name>
    <phone>+82-10-8862-1146</phone>
    <email>ksj1146@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Jae Cho, MPH</last_name>
      <phone>+82-10-9925-7058</phone>
      <email>lungdrcho@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Se Joong Kim, PhD</last_name>
      <phone>+82-10-8862-1146</phone>
      <email>ksj1146@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Young-Jae Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2013</study_first_submitted>
  <study_first_submitted_qc>October 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2013</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
    <mesh_term>Sleep Arousal Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

